investigated the synergistic effects of MSTN inhibitors and GLP-1 agonists by administering apitegromab in combination with semaglutide, a GLP-1 agonist, and tirzepatide, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, in patients with obesity (NCT06445075)
Alex Spinoso
This review is part of the PlexusDx Education Hub, our evidence-based reading on GLP-1 therapy, weight management protocols, and the genetics that shape metabolic outcomes
MHRA approves GLP-1 receptor agonist semaglutide (Wegovy) to reduce risk of serious heart problems in obese or overweight adults
According to researchers, such stressful conditions lead to altered measures of immune function & increased susceptibility to a variety of diseases (41)
While comprehensive PPS and close medical oversight may enhance participant safety and data quality, they do not eliminate confounding factors related to self-selected PED use, polypharmacy, and heterogeneous exposure histories